Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia – Pipeline Review, H2 2016, provides an overview of the Acute Myelocytic Leukemia (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 91, 90, 1, 6, 143, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 14, 24 and 10 molecules, respectively.

Acute Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

4SC AG
AB Science SA
AbbVie Inc
Acetylon Pharmaceuticals Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics Sarl
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Affichem SA
Agios Pharmaceuticals Inc
Aileron Therapeutics Inc
AIMM Therapeutics BV
Akinion Pharmaceuticals AB
Alexion Pharmaceuticals Inc
Altor BioScience Corp
Amgen Inc
Antigen Express Inc
Antisense Therapeutics Ltd
APIM Therapeutics AS
Aprea AB
arGEN-X BV
Ariad Pharmaceuticals Inc
Arno Therapeutics Inc
Arog Pharmaceuticals Inc
Array BioPharma Inc
Astellas Pharma Inc
Asterias Biotherapeutics Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Athenex Inc
Aurigene Discovery Technologies Ltd
AVEO Pharmaceuticals Inc
Bayer AG
BCI Pharma
Bellicum Pharmaceuticals Inc
BerGenBio AS
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
BioInvent International AB
BioLineRx Ltd
BioSight Ltd
Blueprint Medicines Corp
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Calithera Biosciences Inc
Cancer Therapeutics CRC Pty Ltd
Cantargia AB
Cantex Pharmaceuticals Inc
Cascadian Therapeutics Inc
Celgene Corp
Cellceutix Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellectis SA
Cellerant Therapeutics Inc
Celyad SA
CharlestonPharma LLC
Cielo Therapeutics Inc
Constellation Pharmaceuticals Inc
Cornerstone Pharmaceuticals Inc
Critical Outcome Technologies Inc
CrystalGenomics Inc
CSPC Pharmaceutical Group Limited
CTI BioPharma Corp
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Company Ltd
DC Prime BV
Deciphera Pharmaceuticals LLC
DiNonA Inc
Eisai Co Ltd
Eli Lilly and Company
Emercell SAS
EntreChem SL
EpiZyme Inc
Erytech Pharma SA
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
FLX Bio Inc
FORMA Therapeutics Inc
Formula Pharmaceuticals Inc
Fortress Biotech Inc
Fujifilm Corp
Gadeta BV
Gamida Cell Ltd
Genentech Inc
Genoscience Pharma
Genosco Inc
Genzyme Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
GlycoMimetics Inc
Golden Biotechnology Corp
H3 Biomedicine Inc
Hanmi Pharmaceuticals Co Ltd
HEC Pharm Co Ltd
Hybrigenics SA
Igenica Biotherapeutics Inc
Ignyta Inc
Immatics Biotechnologies GmbH
Immune Pharmaceuticals Inc
Immune System Key Ltd
ImmunGene Inc
ImmunoGen Inc
Immunomedics Inc
Incyte Corp
Inflection Biosciences Ltd
Interprotein Corp
Io Therapeutics Inc
IPD Therapeutics BV
Jasco Pharmaceuticals LLC
Jazz Pharmaceuticals Plc
Jeil Pharmaceutical Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
JW Pharmaceutical Corp
Kainos Medicine Inc
Karyopharm Therapeutics Inc
Kiadis Pharma NV
Kite Pharma Inc
Komipharm International Co Ltd
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
MacroGenics Inc
Mateon Therapeutics Inc
MaxCyte Inc
medac GmbH
MediGene AG
Medivation Inc
MEI Pharma Inc
Merck & Co Inc
Merck KGaA
Merus NV
Mesoblast Ltd
Millennium Pharmaceuticals Inc
miRagen Therapeutics Inc
Moleculin Biotech Inc
MolMed SpA
Nanovalent Pharmaceuticals Inc
NantKwest Inc
Nemucore Medical Innovations Inc
Nerviano Medical Sciences Srl
Neumedicines Inc
NewLink Genetics Corp
Novartis AG
NuCana BioMed Ltd
Omeros Corp
OncoImmune Inc
Onconova Therapeutics Inc
Oncopeptides AB
OncoTartis Inc
OncoTherapy Science Inc
Oncternal Therapeutics Inc
Ono Pharmaceutical Co Ltd
Otsuka Holdings Co Ltd
Oxford BioTherapeutics Ltd
Panther Biotechnology Inc
Petra Pharma Corp
Pfizer Inc
Pharma Mar SA
Pharmascience Inc
Pharmedartis GmbH
Philogen SpA
Phylogica Ltd
Polaris Pharmaceuticals Inc
ProNAi Therapeutics Inc
Resverlogix Corp
Rich Pharmaceuticals Inc
Sanofi
Sareum Holdings Plc
Seattle Genetics Inc
Sellas Inc
Selvita SA
Senhwa Biosciences Inc
Shire Plc
SialoTec GmbH
Sigma-Tau SpA
SOM Biotech SL
Sorrento Therapeutics Inc
Stemline Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Sunesis Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
SYNIMMUNE GmbH
Syros Pharmaceuticals Inc
TaiGen Biotechnology Co Ltd
Taiho Pharmaceutical Co Ltd
Takara Bio Inc
Takeda Pharmaceutical Company Ltd
Targazyme Inc
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries Ltd
Theravectys SA
Toko Pharmaceutical Industries Co Ltd
Tolero Pharmaceuticals Inc
Tragara Pharmaceuticals Inc
Trillium Therapeutics Inc
Vichem Chemie Research Ltd
VioQuest Pharmaceuticals Inc
Viralytics Ltd
Vyriad Inc
Xencor Inc
Xenetic Biosciences (UK) Ltd
Zenith Capital Corp
ZIOPHARM Oncology Inc